Notify me when Ally Bridge Group (NY) LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 13 | $62,997,127 | +$38,380,195 | -$91,511,676 | -$53,131,481 | ABVX, SLNO, ATAI, IVA, NERV | 13F-HR | 17 Feb 2026, 17:05 |
| Q3 2025 | 18 | $119,439,102 | +$74,328,735 | -$90,386,107 | -$16,057,372 | SLNO, MDGL, ATAI, ASND, LENZ | 13F-HR | 14 Nov 2025, 16:21 |
| Q2 2025 | 24 | $120,180,084 | +$60,688,183 | -$60,136,668 | +$551,515 | VRNA, SLNO, LENZ, MRUS, ULTRAGENYX PHARMACEUTICAL IN | 13F-HR | 14 Aug 2025, 16:31 |
| Q1 2025 | 28 | $110,931,993 | +$38,837,887 | -$36,605,173 | +$2,232,714 | SWTX, VRNA, SLNO, AXSM, TARS | 13F-HR | 15 May 2025, 11:17 |
| Q4 2024 | 30 | $116,635,007 | +$37,332,824 | -$104,110,523 | -$66,777,699 | ITCI, TARS, INSM, AXSM, XENE | 13F-HR | 14 Feb 2025, 09:45 |
| Q3 2024 | 29 | $186,812,980 | +$75,608,853 | -$56,972,673 | +$18,636,180 | INSM, TARS, MRUS, CGON, BPMC | 13F-HR | 14 Nov 2024, 07:30 |
| Q2 2024 | 25 | $167,861,283 | +$71,769,902 | -$90,136,645 | -$18,366,743 | SLNO, SRPT, GERN, MRUS, INSM | 13F-HR | 14 Aug 2024, 07:52 |
| Q1 2024 | 22 | $179,888,036 | +$116,059,077 | -$86,438,800 | +$29,620,277 | BPMC, SLNO, CGON, XENE, VRNA | 13F-HR | 15 May 2024, 06:56 |
| Q4 2023 | 22 | $138,954,350 | +$73,961,854 | -$28,855,703 | +$45,106,151 | ARGX, SLNO, CBAY, XENE, ITCI | 13F-HR | 14 Feb 2024, 07:30 |
| Q3 2023 | 19 | $85,197,876 | +$46,911,345 | -$37,292,407 | +$9,618,938 | MLTX, XENE, ITCI, AXSM, APLS | 13F-HR | 14 Nov 2023, 15:09 |
| Q2 2023 | 17 | $82,561,114 | +$39,238,333 | -$36,493,990 | +$2,744,343 | RETA, VRNA, XENE, CYTK, GERN | 13F-HR | 14 Aug 2023, 16:04 |
| Q1 2023 | 18 | $76,289,095 | +$67,419,116 | -$91,450,869 | -$24,031,753 | VRNA, XENE, BLU, CYTK, MDGL | 13F-HR | 15 May 2023, 11:12 |
| Q4 2022 | 30 | $102,791,176 | +$37,249,409 | -$77,205,622 | -$39,956,213 | RARE, AADI, ACAD, MRSN, GLPG | 13F-HR | 14 Feb 2023, 10:30 |
| Q3 2022 | 39 | $151,465,000 | +$126,346,000 | -$84,073,798 | +$42,272,202 | SGEN, RARE, SNY, KPTI, IRWD | 13F-HR | 14 Nov 2022, 07:38 |
| Q2 2022 | 22 | $109,726,000 | +$30,471,500 | -$35,800,012 | -$5,328,512 | ARGX, MDVL, COGT, LNTH, GH | 13F-HR | 15 Aug 2022, 09:39 |
| Q1 2022 | 21 | $132,073,000 | +$13,055,215 | -$120,816,944 | -$107,761,729 | LNTH, ISEE, GH, ARVN, COGT | 13F-HR | 16 May 2022, 07:04 |
| Q4 2021 | 30 | $286,118,000 | +$68,841,463 | -$51,614,481 | +$17,226,982 | NTRA, ARVN, RGEN, ISO, FATE | 13F-HR | 14 Feb 2022, 07:00 |
| Q3 2021 | 29 | $305,067,000 | +$57,402,040 | -$68,842,275 | -$11,440,235 | NTRA, RGEN, ARVN, MRTX, NUVB | 13F-HR | 15 Nov 2021, 07:24 |
| Q2 2021 | 27 | $356,485,000 | +$105,958,892 | -$149,237,779 | -$43,278,887 | MDVL, NTRA, FATE, SYRS, ARVN | 13F-HR | 16 Aug 2021, 08:30 |
| Q1 2021 | 31 | $413,075,000 | +$87,079,504 | -$51,612,320 | +$35,467,184 | AVIR, MDVL, CERE, SYRS, FATE | 13F-HR | 17 May 2021, 07:35 |
| Q4 2020 | 28 | $387,994,000 | $0 | $0 | $0 | MDVL, AVIR, CERE, SYRS, FATE | 13F-HR | 16 Feb 2021, 07:21 |